Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes Carrie GermanMinu PilvankarAndrzej Przekwas Original Paper 08 August 2019 Pages: 513 - 529
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent Junzhen WuKun WangJing Zhang Original Paper 13 August 2019 Pages: 531 - 541
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients Sophie E. BerendsTamara J. van SteegRon A. A. Mathôt Original Paper Open access 05 September 2019 Pages: 543 - 551
Mathematical modeling of the glucagon challenge test Saeed MasroorMarloes G. J. van DongenMark A. Peletier Original Paper Open access 30 September 2019 Pages: 553 - 564
Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis Ali A. AlhadabJoshua RheinASTRO-CM Study Team Original Paper 04 October 2019 Pages: 565 - 576
Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma Linh NguyenSunny ChapelSteven Lacy Original Paper 21 October 2019 Pages: 577 - 589
Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM A. BrekkanS. JönssonE. L. Plan Original Paper Open access 26 October 2019 Pages: 591 - 604
Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis Nikolaos TsamandourasSridhar DuvvuriSteve Riley Original paper 29 October 2019 Pages: 605 - 616
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates Puneet GaitondeYeamin HuhSteve Riley Original paper 30 October 2019 Pages: 617 - 626
Correction to: Bayesian approach to investigate a two-state mixed model of COPD exacerbations Anna LargajolliMisba BeeraheeShuying Yang Correction Open access 15 November 2019 Pages: 627 - 627